These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 20970679)

  • 1. Sign of the Zodiac as a predictor of survival for recipients of an allogeneic stem cell transplant for chronic myeloid leukaemia (CML): an artificial association.
    Szydlo RM; Gabriel I; Olavarria E; Apperley J
    Transplant Proc; 2010 Oct; 42(8):3312-5. PubMed ID: 20970679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era: a preliminary assessment.
    Simon W; Segel GB; Lichtman MA
    Blood Cells Mol Dis; 2006; 37(2):116-24; discussion 125-7. PubMed ID: 16904348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [HLA-identical sibling allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia in first chronic phase. Analysis of 51 cases].
    He Y; Feng SZ; Wang M; Wei JL; Qin TJ; Zhou Z; Zhai WJ; Qiu LG; Han MZ
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jul; 26(7):389-92. PubMed ID: 16251016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
    Gratwohl A; Brand R; Apperley J; Crawley C; Ruutu T; Corradini P; Carreras E; Devergie A; Guglielmi C; Kolb HJ; Niederwieser D;
    Haematologica; 2006 Apr; 91(4):513-21. PubMed ID: 16533723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
    Faber E; Koza V; Vítek A; Mayer J; Sedlácek P; Zák P; Zapletalová J; Benesová K; Krejcová H; Steinerová K; Maresová I; Cetkovský P
    Vnitr Lek; 2006 Dec; 52(12):1172-80. PubMed ID: 17299910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia.
    Mittal P; Saliba RM; Giralt SA; Shahjahan M; Cohen AI; Karandish S; Onida F; Beran M; Champlin RE; de Lima M
    Bone Marrow Transplant; 2004 May; 33(10):1005-9. PubMed ID: 15048141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic blood stem cell transplantation in chronic myeloid leukaemia-chronic phase following conditioning with busulphan and cyclophosphamide: a follow up report.
    Saikia TK; Parikh PM; Tawde S; Amare-Kadam PS; Rajadhyaksha S; Chhaya S
    Natl Med J India; 2004; 17(2):71-3. PubMed ID: 15141598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: outcome and prognostic factors: the Chronic Myeloid Leukemia Subcommittee of the GETH (Grupo Español de Trasplante Hemopoyético).
    Martínez C; Gomez V; Tomás JF; Parody R; Sureda A; Sanz G; Cañizo C; Díez JL; Boqué C;
    Bone Marrow Transplant; 2005 Aug; 36(4):301-6. PubMed ID: 15968278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extramedullary T lymphoblastic transformation of chronic myeloid leukaemia occurring after double allogeneic transplantation.
    Kell J; Booth M; Jones B; Appleton M; Lim S
    Bone Marrow Transplant; 1998 Oct; 22(8):813-6. PubMed ID: 9827981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of the EBMT risk score in chronic myeloid leukemia in Brazil and allogeneic transplant outcome.
    De Souza CA; Vigorito AC; Ruiz MA; Nucci M; Dulley FL; Funcke V; Tabak D; Azevedo AM; Byington R; Macedo MC; Saboya R; Penteado Aranha FJ; Oliveira GB; Zulli R; Martins Miranda EC; Azevedo WM; Lodi FM; Voltarelli JC; Simões BP; Colturato V; De Souza MP; Silla L; Bittencourt H; Piron-Ruiz L; Maiolino A; Gratwohl A; Pasquini R
    Haematologica; 2005 Feb; 90(2):232-7. PubMed ID: 15710577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.
    Weisser M; Tischer J; Schnittger S; Schoch C; Ledderose G; Kolb HJ
    Haematologica; 2006 May; 91(5):663-6. PubMed ID: 16627251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase.
    Xiao-Jun H; Lan-Ping X; Kai-Yan L; Dai-Hong L; Huan C; Wei H; Yu-Hong C; Jing-Zhi W; Yao C; Xiao-Hui Z; Hong-Xia S; Dao-Pei L
    Ann Med; 2008; 40(6):444-55. PubMed ID: 18608121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants.
    Passweg JR; Walker I; Sobocinski KA; Klein JP; Horowitz MM; Giralt SA;
    Br J Haematol; 2004 Jun; 125(5):613-20. PubMed ID: 15147377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-transplant outcome in chronic myeloid leukaemia.
    Raza S; Ullah K; Ahmed P; Khan B; Kamal MK
    J Coll Physicians Surg Pak; 2008 Oct; 18(10):615-9. PubMed ID: 18940118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
    Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haemopoietic stem cell transplantation in Australia and New Zealand, 1992-2001: progress report from the Australasian Bone Marrow Transplant Recipient Registry.
    Nivison-Smith I; Bradstock KF; Dodds AJ; Hawkins PA; Szer J
    Intern Med J; 2005 Jan; 35(1):18-27. PubMed ID: 15667464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study.
    Bornhäuser M; Kröger N; Schwerdtfeger R; Schafer-Eckart K; Sayer HG; Scheid C; Stelljes M; Kienast J; Mundhenk P; Fruehauf S; Kiehl MG; Wandt H; Theuser C; Ehninger G; Zander AR;
    Eur J Haematol; 2006 Jan; 76(1):9-17. PubMed ID: 16343266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced-intensity conditioning followed by T-cell depleted allogeneic stem cell transplantation for patients with chronic myeloid leukaemia and minimal residual disease at the time of transplant: high risk of molecular relapse.
    Ringhoffer M; Harsdorf Sv; Schmitt M; Wiesneth M; Zenz T; Stilgenbauer S; Greiner J; Döhner K; Marx M; Döhner H; Bunjes D
    Br J Haematol; 2007 Jan; 136(1):127-30. PubMed ID: 17222200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Monitoring bcr-abl mRNA levels by real-time quantitative RT-PCR in chronic myeloid leukemia patients after hematopoietic stem cell transplantation].
    Qin YZ; Li JL; Zhu HH; Ruan GR; Li LD; Zhang Y; Xu LP; Liu DH; Liu YR; Huang XJ; Chen SS; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2006 Aug; 27(8):511-4. PubMed ID: 17172121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia.
    Holowiecki J; Giebel S; Wojnar J; Krawczyk-Kulis M; Markiewicz M; Holowiecka-Goral A; Freund M; Casper J
    Br J Haematol; 2008 Jun; 142(2):284-92. PubMed ID: 18492101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.